Targeting a key pathway in prostate cancer to improve treatment outcomes
Official title: Macrocycle inhibition of beta-catenin mediated transcription in prostate cancer
Funded at New York University School of Medicine · NIH-11094908 · Data updated 2026-11-12
This study is exploring a new way to treat advanced prostate cancer by testing special compounds that might block a pathway linked to aggressive cancer growth, aiming to find better treatment options for patients who aren't responding well to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $684,075 |
| NIH project number | 5R01CA285624-02 |
| Project ID | NIH-11094908 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced or metastatic prostate cancer, particularly those who have developed resistance to current anti-androgen treatments.
✕Less likely to help
Patients with localized prostate cancer or those who have not yet undergone anti-androgen therapy may not benefit from this research.
What this research studies
This research investigates a new approach to treating prostate cancer by focusing on the Wnt/β-catenin signaling pathway, which is often activated in aggressive forms of the disease. The study aims to develop and test novel macrocyclic compounds that can inhibit this pathway, potentially overcoming resistance to current anti-androgen therapies. By utilizing advanced 3D cell culture techniques, researchers will evaluate how these compounds affect prostate cancer cell growth and gene expression. This innovative methodology seeks to provide insights into more effective treatment options for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for patients with advanced prostate cancer.
How similar studies have gone: While targeting the Wnt/β-catenin pathway in prostate cancer is a relatively novel approach, similar strategies have shown promise in other cancers, indicating potential for success.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Logan, Susan K. — New York University School of Medicine
- Study coordinator: Logan, Susan K.
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.